The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses
Abstract
Objective: Neuromyelitis optica (NMO) attacks often are severe, are difficult to treat, and leave residual deficits. Here, we analyzed the frequency, sequence, and efficacy of therapies used for NMO attacks. Methods: A retrospective review was made of patient records to assess demographic/diagnostic data, attack characteristics, therapies, and the short‐term remission status (complete remission [CR], partial remission [PR], no remission [NR]). Inclusion criteria were NMO according to Wingerchuk's 2006 criteria or aquaporin‐4 antibody–positive NMO spectrum disorder (NMOSD). Remission status was analyzed with generalized estimating equations (GEEs), a patient‐based statistical approach. Results: A total of 871 attacks in 185 patients (142 NMO/43 NMOSD, 82% female) were analyzed. The 1,153 treatment courses comprised high‐dose intravenous steroids (HD‐S; n = 810), plasma exchange (PE; n = 192), immunoadsorption (IA; n = 38), other (n = 80), and unknown (n = 33) therapies. The first treatment course led to CR in 19.1%, PR in 64.5%, and NR in 16.4% of attacks. Second, third, fourth, and fifth treatment courses were given in 28.2%, 7.1%, 1.4%, and 0.5% of attacks, respectively. This escalation of attack therapy significantly improved outcome ( p < 0.001, Bowker test). Remission rates were higher for isolated optic neuritis versus isolated myelitis ( p < 0.001), and for unilateral versus bilateral optic neuritis ( p = 0.020). Isolated myelitis responded better to PE/IA than to HD‐S as first treatment course ( p = 0.037). Predictors of CR in multivariate GEE analysis were age (odds ratio [OR] = 0.97, p = 0.011), presence of myelitis (OR = 0.38, p = 0.002), CR from previous attack (OR = 6.85, p < 0.001), and first‐line PE/IA versus HD‐S (OR = 4.38, p = 0.006). Interpretation: Particularly myelitis and bilateral optic neuritis have poor remission rates. Escalation of attack therapy improves outcome. PE/IA may increase recovery in isolated myelitis. Ann Neurol 2016;79:206–216
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
Weinshenker, B. G., O'Brien, P. C., Petterson, T. M., Noseworthy, J. H., Lucchinetti, C. F., Dodick, D. W., Pineda, A. A., Stevens, L. N., & Rodriguez, M. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q · Cited by 894
Jarius, S., Ruprecht, K., Wildemann, B., Kuempfel, T., Ringelstein, M., Geis, C., Kleiter, I., Kleinschnitz, C., Berthele, A., Brettschneider, J., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-14 · Cited by 764
Self-citationEfficient semiparametric estimation of multi-valued treatment effects under ignorability
Cattaneo, M. D. (2010) · Journal of Econometrics · doi:10.1016/j.jeconom.2009.09.023 · Cited by 620
Plasma exchange for severe attacks of CNS demyelination: Predictors of response
Keegan, M., Pineda, A. A., McClelland, R. L., Darby, C. H., Rodriguez, M., & Weinshenker, B. G. (2002) · Neurology · doi:10.1212/wnl.58.1.143 · Cited by 600
Neuromyelitis Optica Study Group (NEMOS), Trebst, C., Jarius, S., Berthele, A., Paul, F., Schippling, S., Wildemann, B., Borisow, N., Kleiter, I., Aktas, O., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7169-7 · Cited by 595
Self-citationEFNS guidelines on diagnosis and management of neuromyelitis optica
Sellner, J., Boggild, M., Clanet, M., Hintzen, R. Q., Illes, Z., Montalban, X., Du Pasquier, R. A., Polman, C. H., Sorensen, P. S., & Hemmer, B. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03066.x · Cited by 461
Self-citationKeegan, M., König, F., McClelland, R., Brück, W., Morales, Y., Bitsch, A., Panitch, H., Lassmann, H., Weinshenker, B., Rodriguez, M., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67102-4 · Cited by 433
Neuromyelitis optica: clinical features, immunopathogenesis and treatment
Jarius, S., Wildemann, B., & Paul, F. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12271 · Cited by 342
Self-citationTherapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica
Watanabe, S., Nakashima, I., Misu, T., Miyazawa, I., Shiga, Y., Füjihara, K., & Itoyama, Y. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506071174 · Cited by 284
Treatment of neuromyelitis optica: review and recommendations
Kimbrough, D. J., Fujihara, K., Jacob, A., Lana-Peixoto, M. A., Isabel Leite, M., Levy, M., Marignier, R., Nakashima, I., Palace, J., de Seze, J., et al. (2012) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2012.06.002 · Cited by 260
Abboud, H., Petrak, A., Mealy, M., Sasidharan, S., Siddique, L., & Levy, M. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515581438 · Cited by 245
Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder
Bonnan, M., Valentino, R., Olindo, S., Mehdaoui, H., Smadja, D., & Cabre, P. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458508100837 · Cited by 202
Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination
Magaña, S. M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.34 · Cited by 200
Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months
Llufriu, S., Castillo, J., Blanco, Y., Ramió-Torrentà, L., Río, J., Vallès, M., Lozano, M., Castellà, M. D., Calabia, J., Horga, A., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b879be · Cited by 193
Plasma exchange for severe optic neuritis: Treatment of 10 patients
Ruprecht, K., Klinker, E., Dintelmann, T., Rieckmann, P., & Gold, R. (2004) · Neurology · doi:10.1212/01.wnl.0000138437.99046.6b · Cited by 170
Self-citationTreatment of Optic Neuritis by Plasma Exchange (Add-On) in Neuromyelitis Optica
Merle, H., Olindo, S., Jeannin, S., Valentino, R., Mehdaoui, H., Cabot, F. A., Donnio, A., Hage, R., Richer, R., Smadja, D., et al. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2012.1126 · Cited by 167
Nakamura, M., Nakazawa, T., Doi, H., Hariya, T., Omodaka, K., Misu, T., Takahashi, T., Fujihara, K., & Nishida, K. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1344-7 · Cited by 145
Kim, S., Kim, W., Huh, S., Lee, K. Y., Jung, I. J., & Kim, H. J. (2013) · Journal of Clinical Neurology · doi:10.3988/jcn.2013.9.1.36 · Cited by 134
Plasma Exchange in Severe Attacks of Neuromyelitis Optica
Bonnan, M., & Cabre, P. (2012) · Multiple Sclerosis International · doi:10.1155/2012/787630 · Cited by 124
Plasma Exchange Therapy in Steroid-Unresponsive Relapses in Patients with Multiple Sclerosis
Trebst, C., Reising, A., Kielstein, J. T., Hafer, C., & Stangel, M. (2009) · Blood Purification · doi:10.1159/000224630 · Cited by 83
Self-citationGeneralized Estimating Equations in Controlled Clinical Trials: Hypotheses Testing
Dahmen, G., & Ziegler, A. (2004) · Biometrical Journal · doi:10.1002/bimj.200310018 · Cited by 64
Diagnostik und Therapie der Neuromyelitis optica
(NEMOS), N. O. S., Trebst, C., Berthele, A., Jarius, S., Kümpfel, T., Schippling, S., Wildemann, B., & Wilke, C. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-3192-4 · Cited by 38
Self-citationMauch, E., Zwanzger, J., Hettich, R., Fassbender, C., Klingel, R., & Heigl, F. (2011) · Der Nervenarzt · doi:10.1007/s00115-011-3324-5 · Cited by 33
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0718-0 · Cited by 899
Self-citationConnelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
Self-citation
Metadata
- Authors
- Kleiter, I., Gahlen, A., Borisow, N., Fischer, K., Wernecke, K., Wegner, B., Hellwig, K., Pache, F., Ruprecht, K., Havla, J., Krumbholz, M., Kümpfel, T., Aktas, O., Hartung, H., Ringelstein, M., Geis, C., Kleinschnitz, C., Berthele, A., Hemmer, B., Angstwurm, K., Stellmann, J., Schuster, S., Stangel, M., Lauda, F., Tumani, H., Mayer, C., Zeltner, L., Ziemann, U., Linker, R., Schwab, M., Marziniak, M., Then Bergh, F., Hofstadt‐van Oy, U., Neuhaus, O., Winkelmann, A., Marouf, W., Faiss, J., Wildemann, B., Paul, F., Jarius, S., Trebst, C., & on behalf of the Neuromyelitis Optica Study Group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2015-11-26
- Volume
- 79
- Issue
- 2
- Pages
- 206-216
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2155049452
- Cited by
- 432
- References
- 26
- FWCI
- 19.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.